B1QB logo

NRx Pharmaceuticals MUN:B1QB Stock Report

Last Price

€0.54

Market Cap

€43.7m

7D

26.2%

1Y

n/a

Updated

27 Mar, 2024

Data

Company Financials +

NRx Pharmaceuticals, Inc.

MUN:B1QB Stock Report

Market Cap: €43.7m

B1QB Stock Overview

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.

B1QB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

NRx Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NRx Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.54
52 Week HighUS$0.66
52 Week LowUS$0.42
Beta0.99
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-97.19%

Recent News & Updates

Recent updates

Shareholder Returns

B1QBDE PharmaceuticalsDE Market
7D26.2%2.3%1.9%
1Yn/a-25.9%7.3%

Return vs Industry: Insufficient data to determine how B1QB performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how B1QB performed against the German Market.

Price Volatility

Is B1QB's price volatile compared to industry and market?
B1QB volatility
B1QB Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: B1QB has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine B1QB's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/aSteve Willardhttps://www.nrxpharma.com

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine.

NRx Pharmaceuticals, Inc. Fundamentals Summary

How do NRx Pharmaceuticals's earnings and revenue compare to its market cap?
B1QB fundamental statistics
Market cap€43.72m
Earnings (TTM)-€33.29m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B1QB income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$36.06m
Earnings-US$36.06m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 28, 2024

Earnings per share (EPS)-0.39
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-162.0%

How did B1QB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.